TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $31.83.

TGTX has been the topic of a number of recent analyst reports. The Goldman Sachs Group increased their target price on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. B. Riley raised their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a report on Wednesday, September 18th.

TG Therapeutics Stock Performance

Shares of TGTX opened at $22.23 on Friday. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $26.41. The business’s fifty day simple moving average is $22.50 and its two-hundred day simple moving average is $18.80. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The company has a market cap of $3.44 billion, a price-to-earnings ratio of 96.65 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same period in the previous year, the company posted ($0.34) EPS. The firm’s revenue was up 357.0% on a year-over-year basis. Research analysts anticipate that TG Therapeutics will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP acquired a new position in shares of TG Therapeutics during the 2nd quarter worth about $36,501,000. Hood River Capital Management LLC purchased a new stake in TG Therapeutics during the first quarter valued at about $22,420,000. Point72 Asset Management L.P. purchased a new stake in shares of TG Therapeutics in the second quarter worth about $10,423,000. Assenagon Asset Management S.A. acquired a new position in shares of TG Therapeutics in the second quarter worth about $8,698,000. Finally, Eventide Asset Management LLC acquired a new stake in TG Therapeutics during the fourth quarter valued at approximately $7,506,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.